Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study
2016 ◽
Vol 43
(8)
◽
pp. 1475-1479
◽
Keyword(s):
Objective.To evaluate the rates of retention and discontinuation of adalimumab (ADA) due to efficacy and safety in Japanese patients with rheumatoid arthritis (RA).Methods.All patients with RA (n = 476) who were treated with ADA in the Tsurumai Biologics Communication Registry were enrolled.Results.The retention rate of ADA was 46% at 5 years. When focusing on insufficient efficacy, previous biologics use and high baseline disease activity were significant risk factors for up to 1 year. Methotrexate (MTX) use was a significantly low risk factor after 1 year of treatment.Conclusion.Concomitant MTX contributes to the longterm efficacy of ADA therapy.
2012 ◽
Vol 24
(4)
◽
pp. 1257-1265
◽
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 768.3-769
2013 ◽
Vol 71
(Suppl 3)
◽
pp. 589.3-590
2015 ◽
Vol 25
(3)
◽
pp. 373-378
◽
2015 ◽
Vol 10
(1)
◽
2008 ◽
Vol 26
(5)
◽
pp. 499-505
◽
2018 ◽
Vol 13
(4)
◽
pp. 295-304
◽
2017 ◽
Keyword(s):